139693-52-0

Usage

Uses

Used in Pharmaceutical Industry:
6-cyclopropyl-8,9-difluoro-7-methoxy-4-oxo-4,6-dihydro-2H-1l3-[1,3]dioxino[5,6-c]quinoline-2,2-diyl diacetate is used as a potential pharmaceutical compound for its in vitro antibacterial activity. The compound is studied for its ability to inhibit bacterial growth, making it a candidate for the development of new antibiotics to combat drug-resistant bacteria.
Used in Chemical Research:
In the field of chemical research, 6-cyclopropyl-8,9-difluoro-7-methoxy-4-oxo-4,6-dihydro-2H-1l3-[1,3]dioxino[5,6-c]quinoline-2,2-diyl diacetate can be used as a starting material or intermediate in the synthesis of other complex organic molecules. Its unique structure may provide insights into the development of new chemical reactions and methodologies.
Used in Material Science:
The compound's specific properties, such as its fluorinated and cyclopropyl groups, may make it suitable for use in the development of new materials with unique characteristics. It could potentially be utilized in the creation of advanced materials for various applications, including electronics, coatings, or adhesives.

Upstream product

• 11113-50-1 boric acid 
• 108-24-7 acetic anhydride 
• 112811-72-0 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid 
• 4887-24-5 triacetoxyborane 
• 112811-71-9 ethyl 8-methoxy-1-cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylate 
• 1103242-32-5 boron trioxide 

Downstream Products

• 186826-86-8 moxifloxacin hydrochloride 
• 1446946-23-1 7-[3-amino-4-(4'-bromo-2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-25-3 7-[3-amino-4-(2',5'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-26-4 7-[3-amino-4-(3',5'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-27-5 7-[3-amino-4-(2',3'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-28-6 7-[3-amino-4-(3',4'-dimethoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-30-0 7-[3-amino-4-(2'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-31-1 7-[3-amino-4-(3'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-32-2 7-[3-amino-4-(4'-methoxybenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-33-3 7-[3-amino-4-(4'-fluorobenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-34-4 7-[3-amino-4-(4'-chlorobenzyloxyimino)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1446946-35-5 7-(3-amino-4-benzyloxyiminopiperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 1394029-14-1 moxifloxacin hydrochloride 
• 172426-88-9 7-amino-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxoquinoline-3-carboxylic acid 

Relevant academic research and scientific papers

Synthesis method of moxifloxacin hydrochloride oxide impurity

The invention relates to a synthesis method of a moxifloxacin hydrochloride oxide impurity as shown in a formula I-1. The method comprises the following steps: step 1) reacting a compound I-5 with a compound I-4 to obtain a compound I-6; and 2) removing a protecting group from the compound I-6 prepared in the step 1) under an acidic condition to obtain a compound I-1, namely the moxifloxacin hydrochloride oxide impurity.

Preparation method of moxifloxacin hydrochloride (by machine translation)

The invention relates to a preparation method of moxifloxacin hydrochloride. , 1 - Cyclopropyl -7 - (S, S-2, diazabicyclo [4.3.0] nonane -8 - yl) -6 - fluoro -8 - methoxy -4 - oxo -1, 4 - dihydro -3 - quinoline carboxylic acid hydrochloride is prepared. The condensation reaction solvent acetonitrile is recovered after a certain technical means is recovered to form a condensation product borane chelating moxifloxacin, and the condensation reaction solvent acetonitrile can be reused for the condensation reaction step after the condensation reaction solvent acetonitrile is recovered by a certain technical means. The condensate is hydrolyzed with sodium hydroxide solution in acetone, and then pH is adjusted to acid by hydrochloric acid to form a moxifloxacin hydrochloride crude product, and the crude product is refined after refining in a mixture of ethanol and water to obtain refined moxifloxacin hydrochloride. To the method, the condensation reaction temperature is reduced, the product purity is improved, the emission of three wastes is reduced, the production cost is reduced, and the method is suitable for industrial production. (by machine translation)

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride, and the preparation method comprises the following steps: (1) preparing 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate, and (2) carrying out a reaction on the 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate; (2)adding the 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinoline-3-carboxylic acid-O3,O4-boron diacetate and (S,S)-2,8-diazabicyclo[4.3.0]nonane in a solvent in the presence of an acid-binding agent to obtain a borane condensate, removing the solvent, dissolving the borane condensate in water, and adding hydrochloric acid to form salt and crystallize to obtain moxifloxacin hydrochloride. According to the preparation method, the borane condensate is dissolved in water, and hydrochloric acid is added for salifying and crystallizing, so that genotoxic impurities such as chloromethaneand chloroethane are not generated, and an impurity C is not generated; therefore, moxifloxacin hydrochloride prepared by means of the preparation method is high in purity and low in risk.

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride. The method comprises the following steps: performing condensation by using 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-ethylquinolinecarboxylate as a central ring, and (S,S)-2,8-diazabicyclo[4,3,0]nonane as a side chain, after alkali hydrolysis is completed, adding a part of 6N hydrochloric acid, performing primary crystallization, adding the remaining 6N hydrochloric acid, performing secondary crystallization, and performing recrystallization on the crystallized product obtain by the secondary crystallization once by using ethanol to obtain the moxifloxacin hydrochloride with a high content and excellent quality. When the method provided by the invention is adopted to prepare the moxifloxacin hydrochloride, product loss caused by repeated crystallization is reduced, labor intensity is reduced, energy consumption is reduced, product stability is improved, product quality is greatly improved, and themethod is suitable for industrialized large-scale production; and the prepared moxifloxacin hydrochloride contains 99.6%-102.0% of C21H25ClFN3O4 calculated by an anhydrate, and has a low total impurity content.

Moxifloxacin hydrochloride new preparation method

The invention provides a method for preparing a moxifloxacin intermediate and moxifloxacin hydrochloride, which comprises the following steps: carrying out condensation reaction on main ring chelate disclosed as Formula (I) and (S,S)-2,8-diazabicyclo-[4.3.0]nonane in the presence of an acid acceptor in a solvent, acidifying for salification, crystallizing, filtering, washing and drying to obtain the moxifloxacin hydrochloride. The method is characterized in that the solvent in the condensation reaction is alcohol. The condensation reaction is carried out in the alcohol solvent at the controlled temperature of 30-80 DEG C (preferably lower temperature), so the method has the advantage of mild reaction conditions, greatly reduces the generation of impurities, saves the energy; the alcohol solvent can be directly acidified after sufficient reaction, thereby saving the complex step of removing acetonitrile by evaporation and greatly simplifying the steps; and the method is suitable for industrial production.

Preparation method of high-purity moxifloxacin hydrochloride impurity I

The invention discloses a preparation method of a high-purity moxifloxacin hydrochloride impurity I. The preparation method comprises the following steps: using 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinoline carboxylic acid or ester thereof as a starting raw material; carrying out borate reaction, azido reaction, hydrolysis reaction and reduction reaction to obtain the moxifloxacin hydrochloride impurity I. The impurity I product obtained by the preparation method disclosed by the invention has the advantages of high purity and high yield.

A high-purity hydrochloric acid moxifolxacin method for the synthesis of (by machine translation)

The present invention provides a high-purity hydrochloric acid method for synthesizing moxifolxacin, comprising the following steps: the benzol the 1-cyclopropyl -6,7-difluoro-8-methoxy -1,4-dihydro-4-oxo-quinolyl-3-carboxylic acid ethyl ester carbonyl of protection, then the (S, S) - 2,8-diazabicyclo [4.3.0] nonane after to conduct the condensation reaction, to adopt the hydrochloric acid is deprotected, star thick mozambican Xisha hydrochloric acid obtained; the resulting star thick mozambican Xisha of the hydrochloric acid aqueous solution of alkali is dissolved, then extracting with an organic solvent, removal of the organic phase, the aqueous phase by adding hydrochloric acid to adjust pH in value to acidity, then crystallization, filtering to obtain the filter cake, then the aqueous organic solvent to the obtained filter cake of performing recrystallization, final filtering, drying to obtain high-purity hydrochloric acid Moxifloxacin. The method of the invention high purity of the prepared product, high yield, good reproducibility, has extremely strong the feasibility of industrial operation. (by machine translation)

Preparation method of moxifloxacin impurity G compound

The invention provides a preparation method of a moxifloxacin impurity G compound, comprising using 1-cyclopropyl-6,7-difluoro-8-methoxy-1,4-dihydro-4-oxoquinolyl-3-carboxylic acid ethyl ester as a starting material to react with triacetoxyboron, then removing ethyl ester to generate moxifloxacin boron diacetate, reacting with (S,S)-2,8-diazabicyclo[4.3.0]nonane, then removing a protective base and salifying to generate moxifloxacin hydrochloride, oxidizing via an oxidizing agent, and then acquiring moxifloxacin impurity G in the presence of a dewatering agent. The preparation method is simple to perform, a prepared target product has high purity, and an obtained substance is useful for studying moxifloxacin hydrochloride related substances.

Preparation method of moxifloxacin hydrochloride

The invention discloses a preparation method of moxifloxacin hydrochloride. The method includes the following steps of making boric acid and acetic anhydride make contact and react for 1 h at a temperature of 85-105 DEG C in protection gas, lowering the temperature to 75-80 DEG C, adding a stable promoter and 1-cyclopropyl-6,7-difluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid ethyl ester, continuing to conduct stirring for the reaction for 1.5-3 h at a temperature of 75-80 DEG C, conducting monitoring and tracking till the reaction ends, cooling to the room temperature, adding acetonitrile and organic amine to make the mixture react with (S,S)-2,8-diazabicyclo[4.3.0]nonane for 1-2 h at a temperature of 60-70 DEG C, cooling to the room temperature, adding methyl alcohol, dropwise adding concentrated hydrochloric acid at a temperature of 5-10 DEG C, adjusting the pH value to 1-3, conducting stirring for 2 h, cooling to a temperature of -10 DEG C to -5 DEG C, conducting crystallization and suction filtration, conducting washing through cold ethyl alcohol, conducting decompression drying, and obtaining moxifloxacin hydrochloride. The stable promoter is selected from one or more of glycine, serine and threonine. The method is high in yield, simple in operation and aftertreatment and suitable for industrial production.

A hydrochloric acid moxifolxacin method for the synthesis of

The invention provides a synthetic method of moxifloxacin hydrochloride. The synthetic method comprises the following steps: by taking a primary ring chelate as shown in a formula (I) and (S, S)-2,8-diazabicyclo[4.3.0] nonane as raw materials and taking triethylamine as an acid absorber, carrying out condensation reaction in acetonitrile sufficiently; and concentrating, treating, then dissolving, carrying out acidolysis and salifying, crystallizing, filtering, washing and drying to obtain the moxifloxacin hydrochloride, wherein a weight ratio of the primary ring chelate to acetonitrile to triethylamine to (S, S)-2,8-diazabicyclo[4.3.0] nonane is 1 to (2-10) to (0.08-0.96) to (0.30-0.59). The synthetic method is characterized in that a condensation reaction temperature is larger than and equal to 30 DEG C and lower than 70 DEG C. The synthetic method has the following technical effects that nucleophilic substitution reaction is carried out in acetonitrile at a temperature not lower than 30 DEG C but lower than 70 DEG C, the reaction conditions are gentle, the production of impurities is greatly reduced and the energy resources are saved. After acetonitrile is evaporated, the treatment method is simple and rapid, acidification is carried out in alcohol to obtain moxifloxacin hydrochloride, and thus, the synthetic method is suitable for industrial production.